BiotechTube

DS-9231 + Placebo

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Embolism

Conditions

Pulmonary Embolism

Trial Timeline

Jan 1, 2018 → Feb 1, 2020

NCT ID
NCT03316729

About DS-9231 + Placebo

DS-9231 + Placebo is a phase 2 stage product being developed by Daiichi Sankyo for Pulmonary Embolism. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03316729. Target conditions include Pulmonary Embolism.

What happened to similar drugs?

20 of 20 similar drugs in Pulmonary Embolism were approved

Approved (20) Terminated (1) Active (0)
✅MonteplaseEisaiApproved
✅lysozyme 90 mg + PlaceboEisaiApproved
✅tadalafil and ambrisentan upfront combination therapyEli LillyApproved
✅Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
✅Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
✅Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03316729Phase 2Withdrawn

Competing Products

20 competing products in Pulmonary Embolism

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
32
macitentan 10 mgBML, Inc.Phase 3
32
tadalafil + tadalafilEli LillyPhase 3
40
CS1 AdministrationCereno ScientificPhase 2
29
CS1Cereno ScientificPre-clinical
24
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
36
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
25
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
39
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
32
RegadenosonAstellas PharmaPre-clinical
18
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
MonteplaseEisaiApproved
43
lysozyme 90 mg + PlaceboEisaiApproved
43
Prednisolone + VoriconazoleCiplaPhase 2/3
38
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
35
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
43
Tadalafil- Tablet or Oral suspensionEli LillyPhase 1/2
32